Harvard Bioscience (NASDAQ:HBIO – Get Rating) had its target price trimmed by KeyCorp from $10.00 to $7.00 in a research report sent to investors on Friday morning, MarketBeat.com reports. The firm currently has an overweight rating on the medical instruments supplier’s stock.
Separately, TheStreet cut shares of Harvard Bioscience from a c rating to a d+ rating in a research report on Monday, May 23rd.
Harvard Bioscience Trading Down 1.9 %
Shares of HBIO opened at $3.53 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.13 and a current ratio of 2.18. Harvard Bioscience has a 52-week low of $3.25 and a 52-week high of $8.75. The firm has a market cap of $145.58 million, a price-to-earnings ratio of -39.22 and a beta of 1.71. The business’s fifty day moving average is $3.70 and its 200-day moving average is $4.82.
Insiders Place Their Bets
In other news, CEO James W. Green purchased 10,000 shares of the business’s stock in a transaction dated Monday, May 9th. The shares were purchased at an average cost of $3.40 per share, with a total value of $34,000.00. Following the completion of the purchase, the chief executive officer now owns 2,319,955 shares of the company’s stock, valued at approximately $7,887,847. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.20% of the company’s stock.
Hedge Funds Weigh In On Harvard Bioscience
A number of hedge funds have recently modified their holdings of HBIO. Greenwood Capital Associates LLC increased its holdings in Harvard Bioscience by 1.9% in the fourth quarter. Greenwood Capital Associates LLC now owns 216,363 shares of the medical instruments supplier’s stock valued at $1,525,000 after purchasing an additional 3,950 shares during the period. Lazard Asset Management LLC raised its position in shares of Harvard Bioscience by 230.5% during the first quarter. Lazard Asset Management LLC now owns 7,120 shares of the medical instruments supplier’s stock worth $44,000 after acquiring an additional 4,966 shares during the last quarter. Amalgamated Bank acquired a new position in shares of Harvard Bioscience in the first quarter worth approximately $38,000. Bank of America Corp DE boosted its holdings in Harvard Bioscience by 44.9% in the first quarter. Bank of America Corp DE now owns 25,755 shares of the medical instruments supplier’s stock valued at $160,000 after acquiring an additional 7,976 shares during the last quarter. Finally, Strs Ohio increased its position in Harvard Bioscience by 9.0% during the 1st quarter. Strs Ohio now owns 114,000 shares of the medical instruments supplier’s stock valued at $707,000 after purchasing an additional 9,400 shares during the period. Institutional investors and hedge funds own 72.75% of the company’s stock.
About Harvard Bioscience
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.
- Get a free copy of the StockNews.com research report on Harvard Bioscience (HBIO)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.